Abstract Details

Title Reproduction and the Risk of Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) S10 - (-)

Poster/Presentation
Number 005

Background The incidence of relapsing remitting multiple sclerosis (MS) in Denmark has doubled in women since 1970 and in the same period only a small increase in men was observed.

Objective

Design/Methods The cohort consisted of 1403 patients with probable/definite MS of both sexes, identified through the nationwide Danish Multiple Sclerosis Registry, with clinical onset between 2000 and 2004, aged 15-55 at onset. For each case, 25 control persons were drawn by random from the Danish Civil Registration System (CRS) matched by sex, year of birth and residential municipality by January 1st in the year of onset of the first demyelinating symptom of the corresponding MS-case.

Results More female cases than controls had no childbirths or fewer births before clinical onset (p=0.018) but only in the last five years preceding onset (p<0.0001). Childbirths within five years before clinical onset reduced the risk of MS onset in women OR=0.44 (95 % CI 0.31-0.61, p<0.001) for one child and OR= 0.71 (95 % CI 0.57-0.88, p=0.002) for more than one children. The risk of MS was not influenced by parity in men. Induced abortions within 5 years before clinical onset were more common in controls compared to cases OR=0.70 (95% CI 0.51-0.86, p=0.026). Parental age at first childbirth (in five-year age groups) had no effect on the risk of MS .In the five years before the year of clinical onset, the social behavior, in terms of broken partnerships and annual mean income, did not differ between cases and controls.

Conclusions Considering the possibility of reversed causation, which was not supported, by the data, pregnancy could exert a certain protection against MS on a biological basis, lasting up to five years.

Authors/Disclosures
Melinda Magyari, MD PRESENTER	Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi.
Nils Koch-Henriksen, MD (Dept of Neurology, Aalborg Hospital)	Dr. Koch-Henriksen has nothing to disclose.
Claudia Christina H. Kristensen, MD (Aalborg University Hospital)	No disclosure on file
Per Solberg Sorensen, MD, PhD, FAAN (Rigshospitalet Glostrup)	Dr. Sorensen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Sorensen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Sorensen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Sorensen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TEVA.
Nathan B. Fountain, MD, FAAN (University of Virginia)	Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Fountain has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Coda. Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Fountain has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Fountain has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BrainStorm. Dr. Fountain has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Shackleford. Dr. Fountain has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Acumen. Dr. Fountain has stock in Hexokine.

��ɫ��

��ɫ��